0 116

Cited 0 times in

Pentraxin 3 as an Immune Recovery Marker in HIV Infection After Combination Antiretroviral Therapy

Authors
 Eun Hwa Lee  ;  Jung Ah Lee  ;  Chang Hyup Kim  ;  Ki Hyun Lee  ;  Jinnam Kim  ;  Jung Ho Kim  ;  Jin Young Ahn  ;  Nam Su Ku  ;  Jun Yong Choi  ;  Joon-Sup Yeom  ;  Su Jin Jeong 
Citation
 AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol.40(2) : 110-113, 2024-02 
Journal Title
AIDS RESEARCH AND HUMAN RETROVIRUSES
ISSN
 0889-2229 
Issue Date
2024-02
MeSH
Antiretroviral Therapy, Highly Active ; Biomarkers ; C-Reactive Protein* ; HIV Infections* / drug therapy ; Humans ; Inflammation ; Prospective Studies ; Serum Amyloid P-Component*
Keywords
chronic inflammation ; human immunodeficiency virus ; pentraxin 3
Abstract
Abstract

Human immunodeficiency virus (HIV) infection causes chronic inflammation in affected individuals. Chronic inflammation may hinder immunological recovery. Treatment with combination antiretroviral therapy (cART) is insufficient to reduce inflammation. Pentraxin 3 (PTX3) is an inflammatory marker associated with cardiovascular disease, malignancy, and acute infection. This study evaluated the usefulness of serum PTX3 levels in measuring inflammation levels, which may be associated with the probability of immune recovery in people living with HIV (PLH). In this single-center prospective study, we measured serum PTX3 levels in PLH treated with cART. Clinical information on HIV status, type of cART administered, and CD4+ and CD8+ T cell counts at the initial diagnosis of HIV and at study enrollment was obtained from each participant. PLH were divided into good and poor responder groups according to their CD4+ T cell counts at enrollment. A total of 198 PLH were enrolled in this study. A total of 175 and 23 participants were assigned to the good and poor responder groups, respectively. The poor responder group exhibited higher PTX3 levels (0.53ng/mL vs. 1.26ng/mL, p=.032). Logistic regression analysis demonstrated that low body mass index [odds ratio (OR)=0.8, p=.010], low initial CD4+ T cell counts at diagnosis (OR=0.994, p=.001), and high PTX3 levels (OR=1.545, p=.006) are clinical factors that were significantly associated with poor immune recovery in PLH. According to the Youden index, PTX3 levels >1.25ng/mL are associated with poor immune recovery. PLH should be clinically, virologically, and immunologically evaluated. Serum PTX level is a useful inflammatory marker associated with immune recovery in PLH treated with cART.
Full Text
https://www.liebertpub.com/doi/10.1089/AID.2023.0002
DOI
10.1089/aid.2023.0002
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ku, Nam Su(구남수) ORCID logo https://orcid.org/0000-0002-9717-4327
Kim, Jung Ho(김정호) ORCID logo https://orcid.org/0000-0002-5033-3482
Kim, Jin Nam(김진남)
Ahn, Jin Young(안진영) ORCID logo https://orcid.org/0000-0002-3740-2826
Yeom, Joon Sup(염준섭) ORCID logo https://orcid.org/0000-0001-8940-7170
Lee, Ki Hyun(이기현)
Lee, Eun Hwa(이은화)
Lee, Jung Ah(이정아)
Jeong, Su Jin(정수진) ORCID logo https://orcid.org/0000-0003-4025-4542
Choi, Jun Yong(최준용) ORCID logo https://orcid.org/0000-0002-2775-3315
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/198405
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links